8-K: CEL-SCI Implements Shareholder Rights Plan

CEL-SCI Corporation's Board of Directors has adopted a Shareholder Rights Agreement, commonly known as a 'poison pill,' to protect against coercive takeover attempts and ensure fair value for shareholders.

Summary

• The Board of Directors of CEL-SCI Corporation approved a Shareholder Rights Agreement on November 18, 2025.
• The plan declares a dividend of one Series A Right and one Series B Right for each Common Share outstanding on October 30, 2025, and for shares issued thereafter until the Distribution Date, Redemption Date, or Final Expiration Date.
• The 'Distribution Date' is triggered when a person or group acquires beneficial ownership of 15% or more of the outstanding Common Stock, or publicly announces an intention to commence a tender offer that would result in 15% or more ownership.
• Each Series A Right initially entitles the holder to purchase one share of Common Stock at a 'Purchase Price' equal to 20% of the current per share market price of the Company's Common Stock, subject to adjustments.
• If a person becomes an 'Acquiring Person' (beneficial owner of 15% or more, with certain exceptions), their Rights become null and void, while other holders' Series A Rights adjust to allow purchase of Common Stock at a significant discount (a 'flip-in' event).
• In the event of certain major corporate transactions (e.g., merger where CEL-SCI is not the survivor, sale of 50% or more of assets/earning power), Series B Rights will entitle holders to purchase common stock of the acquiring company at a 50% discount (a 'flip-over' event), with an initial exercise price of $100.
• The Rights will expire on October 30, 2030, unless earlier redeemed or exchanged.
• The Board of Directors can redeem all Rights at a 'Redemption Price' of $0.0001 per Right prior to the Distribution Date. After a person becomes an Acquiring Person, redemption is only possible if a majority of directors are 'Continuing Directors'.
• The Board can also exchange Rights for Common Stock (1:1 ratio) after a person becomes an Acquiring Person, but before they own 50% or more, provided a majority of directors are 'Continuing Directors'.

Sentiment

Score: 4

Explanation: The implementation of a shareholder rights plan is a defensive corporate governance measure. While it aims to protect shareholder value by deterring hostile takeovers and encouraging fair negotiations, it can also be viewed negatively as it may entrench management and deter potentially beneficial acquisition offers at a premium. The score reflects a slightly cautious to neutral sentiment, acknowledging both protective aspects and potential limitations on shareholder liquidity/premium opportunities.

Positives

• Protects shareholders from coercive or unfair takeover tactics by making it more difficult and expensive for an 'Acquiring Person' to gain control without Board approval.
• Encourages potential acquirers to negotiate directly with the Board of Directors, potentially leading to better terms for all shareholders.
• Aims to ensure that all shareholders receive fair value in the event of a change of control.

Negatives

• May deter legitimate acquisition offers that could otherwise provide a premium to shareholders, as the 'poison pill' makes such transactions more complex and costly.
• Could entrench current management and the Board of Directors by making it harder for activist investors or other parties to gain influence or control.
• The complexity of the rights plan may be difficult for average investors to fully understand.

Risks

• The Shareholder Rights Plan may deter potential acquisition offers, even those that could be beneficial to shareholders.
• The plan could lead to management entrenchment, reducing accountability to shareholders.
• The effectiveness of the plan relies on the Board of Directors, particularly 'Continuing Directors,' making decisions in the best interest of all shareholders.

Future Outlook

The Shareholder Rights Plan is designed to influence future corporate control transactions by deterring unsolicited or coercive takeover attempts. It aims to ensure that any acquisition of the Company occurs on terms approved by the Board of Directors, thereby protecting shareholder value. The plan will remain in effect until October 30, 2030, unless redeemed or exchanged earlier.

Industry Context

Shareholder Rights Plans, or 'poison pills,' are a common defensive strategy employed by companies across various industries to protect against hostile takeovers. They are typically implemented to give the board more leverage in negotiations with potential acquirers and to prevent 'creeping control' acquisitions that do not offer a premium to all shareholders. This action by CEL-SCI aligns with a standard corporate governance practice for companies seeking to maintain strategic independence.

Comparison to Industry Standards

• The 15% threshold for triggering an 'Acquiring Person' status is a common benchmark in shareholder rights plans across various industries, designed to prevent accumulation of significant stakes without board engagement.
• The 'flip-in' and 'flip-over' provisions are standard features of modern poison pills, providing robust protection against both open market accumulations and subsequent business combinations.
• The redemption price of $0.0001 per Right is typical for such plans, making redemption a nominal cost for the company if the board decides to remove the pill.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Provides protection against coercive takeover attempts and aims to ensure fair value in a change of control scenario. However, it may also deter offers that could result in a premium for their shares.
• **Potential Acquirers:** Significantly increases the cost and complexity of acquiring a substantial stake or control of the Company without the Board's approval, thereby discouraging hostile bids.
• **Management and Board of Directors:** Strengthens their position and control over the Company's strategic direction by providing a strong defense mechanism against unwanted takeovers, potentially leading to entrenchment.

Next Steps

• The Company will send a Summary of Rights to Purchase Common Stock to each record holder of Common Stock as of October 30, 2025.
• Separate Right Certificates will be distributed as soon as practicable after the 'Distribution Date' occurs.
• The Company will prepare and file a registration statement under the Securities Act of 1933 with respect to the Rights and the securities purchasable upon exercise of the Rights, and use best efforts to cause it to become effective.

Key Dates

Recommendation

The implementation of a Shareholder Rights Plan is a defensive corporate governance action, not a direct indicator of operational performance or financial health. While it aims to protect long-term shareholder value by deterring hostile takeovers and encouraging negotiated transactions, it can also limit the potential for a short-term acquisition premium. For a seasoned investor, this move suggests the company is preparing to defend its independence, which could be seen as a commitment to its current strategy but also a potential barrier to liquidity events. Without additional financial or operational data, a 'hold' recommendation is appropriate, as the filing itself does not provide a basis for a strong buy or sell, but rather signals a change in the company's defensive posture.

Keywords

Shareholder Rights Plan, Poison Pill, Anti-Takeover Defense, Corporate Governance, Hostile Takeover, Acquiring Person, Tender Offer, Common Stock, CEL-SCI Corporation